Silexion Therapeutics (SLXN) Accounts Payables (2023 - 2026)
Silexion Therapeutics (SLXN) posted quarterly Accounts Payables of $912000.0 for Q1 2026, up 26.32% year-over-year from $722000.0 in Q1 2025, and little changed quarter-over-quarter from $910000.0 in Q4 2025.
Silexion Therapeutics (SLXN) Accounts Payables (2023 - 2026) Analysis & Trends
Silexion Therapeutics' Accounts Payables history runs 4 years deep, the most recent figure standing at $912000.0 for Q1 2026.
- In Q1 2026, Accounts Payables rose 26.32% year-over-year to $912000.0; the TTM figure through Mar 2026 stood at $912000.0 (up 26.32% YoY), while the FY2025 annual figure was $910000.0, down 2.05% from the prior year.
- Accounts Payables for Q1 2026 stood at $912000.0, roughly flat from $910000.0 in the prior quarter.
- The five-year high for Accounts Payables was $946000.0 in Q3 2025, with the low at $281000.0 in Q2 2024.
- The 4-year median for Accounts Payables is $799000.0 (2024), against an average of $723333.3.
- The sharpest annual moves came in 2024 and 2025: Accounts Payables soared 191.22% in 2024, then decreased 2.05% in 2025.
- Silexion Therapeutics' Accounts Payables stood at $319000.0 in 2023, then jumped by 191.22% to $929000.0 in 2024, then fell by 2.05% to $910000.0 in 2025, then grew by 0.22% to $912000.0 in 2026.
- Business Quant data shows SLXN's Accounts Payables at $912000.0 in Q1 2026, $910000.0 in Q4 2025, and $946000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Silexion Therapeutics | 266,692.97 | -1.96 Mn | - | 1.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.18 Mn |
| Mar 31, 2026 | 912,000.00 |
| Dec 31, 2025 | 910,000.00 |
| Sep 30, 2025 | 946,000.00 |
| Jun 30, 2025 | 692,000.00 |
| Mar 31, 2025 | 722,000.00 |
| Dec 31, 2024 | 929,000.00 |
| Sep 30, 2024 | 799,000.00 |
| Jun 30, 2024 | 281,000.00 |
| Dec 31, 2023 | 319,000.00 |